Brigit Riley - 15 Mar 2023 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ADVM
Reported as of: 15 Mar 2023
Net transaction value: -$5,705
SEC form: 4
Accepted by SEC: 17 Mar 2023, 18:02:59 UTC
Prior SEC filing: 03 Mar 2023
Source filing: View source filing
Reporting owner signature: Brigit Riley, by /s/ Ron A. Metzger, Attorney-in-Fact

Key filing fact

Brigit Riley filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 17 Mar 2023.

Key facts

This page summarizes Brigit Riley's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Mar 2023, 18:02.

Change

Previous filing in this sequence was filed on 03 Mar 2023.
Current net transaction value: -$5,705.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADVM transaction

Common Stock

Sale

Transaction value: $5,705
Shares: -7,299
Change %: -5.9%
Price: $0.7816
Shares after: 117,435
Date: 15 Mar 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.

Footnote F2

Includes 6,000 shares purchased on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.